Patent · US Active

Cyclic NTCP-targeting peptides and their uses as entry inhibitors

US11401304B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

Stephan Urban · Neustadt, DE
Yi Ni · Heidelberg, DE
Walter Mier · Bensheim, DE

Key dates

Filing date	Dec 15, 2016
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Dec 15, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.